Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
Key Highlights
- ➤Catheter patent protection extends through November 28, 2042
- ➤Fractyl received USPTO allowance for Revita thermal-dosing patent application
- ➤Fractyl plans U.S. FDA De Novo submission for post-GLP-1 weight maintenance
- ➤Fractyl’s portfolio includes 39 granted U.S. patents and approximately 40 pending applications
- ➤Revita’s REMAIN-1 pivotal cohort reported positive six-month results
Expert Statements
Harith Rajagopalan, Co-Founder and Chief Executive Officer of Fractyl Health
“The positive six-month REMAIN-1 results and our patient research strengthen our confidence in Revita’s potential to address a substantial unmet need in post-GLP-1 weight maintenance by targeting the duodenum”
Harith Rajagopalan, Co-Founder and Chief Executive Officer of Fractyl Health
“As we build the clinical evidence and prepare for potential commercialization, we are also strengthening protection for the innovations behind Revita.”
Harith Rajagopalan, Co-Founder and Chief Executive Officer of Fractyl Health
“Our portfolio spans key device components and duodenal treatment methods, including claims that are not limited to any specific energy modality.”
Harith Rajagopalan, Co-Founder and Chief Executive Officer of Fractyl Health
“We believe this breadth is an important foundation for Revita’s potential long-term commercial value.”
* Patent milestones build on positive REMAIN-1 six-month pivotal results and patient research supporting interest in a one-time procedure for post-GLP-1 weight maintenance * New catheter patent provides protection extending to 2042; broader portfolio includes issued duodenum treatment-method claims not limited to any specific energy modality * Fractyl’s IP portfolio includes 39 granted U.S. patents, approximately 40 pending U.S. applications and more than 50 issued international patents BURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced additions to its U.S. patent portfolio that strengthen the intellectual property foundation for investigational Revita® as the Company advances toward a planned U.S. Food and Drug Administration (FDA) De Novo marketing submission for post-GLP-1 weight maintenance.
Get started
Create a free account to read the full story.